Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Lupus Nephritis Therapies Compared, Plus Naming Guidance for Biosimilars

  |  

References

  1. Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: A Bayesian network meta-analysis of randomized controlled trials. Lupus 2015 Jul 9. 0961203315595131 [Epub ahead of print–abstract]
  2. Kuznar W. Tacrolimus comes out tops for lupus nephritis. Medpage Today. 2015 Jul 24.
  3. U.S. Food and Drug Administration. Nonproprietary naming of biological products; draft guidance for industry; availability. Federal Register. 2015 Aug 28.
  4. American College of Rheumatology. Press release: American College of Rheumatology applauds FDA draft guidance requiring distinct naming for biosimilars. 2015 Aug 28.

Related Articles